Status
Conditions
Treatments
About
Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted options for management. First is the absence of a sensitive and precise measure of cognitive impairment. Second is the absence of an index of disease status linked to brain pathophysiology and cognitive performance. This project overcomes both obstacles to link cognitive impairment to MS disease biomarkers. The absence of a sensitive and precise measure of cognitive impairment, along with the absence of an index of disease status linked to brain pathophysiology and cognitive performance, limits the understanding of the biological basis for multiple sclerosis (MS). This project overcomes both obstacles to link cognitive function to MS disease biomarkers, and provides preliminary evaluation of a disease modifying therapy (Tecfidera) for preserving cognitive function.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Unable or unwilling to provide informed consent.
Beck Depression Inventory-Fast Screen (BDI-FS) [129, 130] score of 4 or more
Current alcohol or other substance use disorder
Primary psychiatric disorder that would adversely influence ability to participate
Other neurological condition associated with cognitive impairment (e.g., epilepsy, brain injury)
Other serious uncontrolled medical condition (e.g., cancer or acute myocardial infarction)
Learned English language after 12 years of age
For low absolute low lymphocyte count (ALC), USPI guidance will be utilized.
For MS participants:
Lemtrada, Cladribine, Mitoxantrone
6 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal